• Citer

A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results

par Wohl, David;Cheret, Antoine;Brunetta, Jason;Mussini, Cristina;Tebas, Pablo;Sax, Paul Edward Dward P.E.;Cheng, Andrew K;Zhong, Lijie;Callebaut, Christian;Das, Moupali;Fordyce, Marshall;Oka, Shinichi;Friborg, Sandra;Villamejor, Kathleen;Huang, Jay;Guo, Susan;Liu, Hui;Wang, Hui;Miller, Michael;Margot, Nicolas;Clumeck, Nathan ;Clarke, Amanda;Brinson, Cynthia;Stephens, Jeffrey;Tashima, Karen;Arribas, Jose;Rashbaum, Bruce
Référence Journal of acquired immune deficiency syndromes, 72, 1, page (58-64)
Publication Publié, 2016-05

Article révisé par les pairs

• Détails
• Contenu

Titre:	A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results
Auteur:	Wohl, David; Cheret, Antoine; Brunetta, Jason; Mussini, Cristina; Tebas, Pablo; Sax, Paul Edward Dward P.E.; Cheng, Andrew K; Zhong, Lijie; Callebaut, Christian; Das, Moupali; Fordyce, Marshall; Oka, Shinichi; Friborg, Sandra; Villamejor, Kathleen; Huang, Jay; Guo, Susan; Liu, Hui; Wang, Hui; Miller, Michael; Margot, Nicolas; Clumeck, Nathan; Clarke, Amanda; Brinson, Cynthia; Stephens, Jeffrey; Tashima, Karen; Arribas, Jose; Rashbaum, Bruce
Informations sur la publication:	Journal of acquired immune deficiency syndromes, 72, 1, page (58-64)
Statut de publication:	Publié, 2016-05
Sujet CREF:	Pharmacologie
	Pathologie maladies infectieuses
Mots-clés:	Bone mineral density
	HIV
	Integrase inhibitor
	Randomized controlled trial
	Renal safety
	Tenofovir alafenamide
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1525-4135
	info:doi/10.1097/QAI.0000000000000940
	info:scp/84973121361
	info:pmid/26829661